Cardiovascular health, heart failure, atherosclerosis, and cardiac research
460 articles
Real-world study of 1,559 octogenarians finds SGLT2 inhibitors reduce all-cause death by 42% and heart failure rehospitalization by 31% with no increase in adverse events.
A decade of US data reveals persistent underuse of single-pill combination therapy for hypertension, despite its superiority for blood pressure control.
A major JACC study exposes how secondary prevention after myocardial infarction falls short across the U.S. population.
AI-driven analysis of fat surrounding the heart may unlock a powerful new tool for predicting heart failure before symptoms emerge.
FOURIER and FOURIER-OLE data suggest that earlier initiation of the PCSK9 inhibitor evolocumab may reduce arterial aneurysm events.
The DECISION trial finds low-dose digoxin did not significantly cut hospitalizations or cardiovascular death in 1,001 HFrEF/HFmrEF patients.
A phase 2 trial of the microRNA-132 inhibitor CDR132L showed safety but no significant improvement in cardiac remodeling after heart attack.
A 2025 review maps the molecular drivers of cardiac aging and evaluates drugs, CRISPR, stem cells, and lifestyle as countermeasures.
The PRAISE-MR trial finds sacubitril/valsartan significantly improves exercise hemodynamics and quality of life in a high-risk HFpEF phenotype.
A JAMA meta-analysis of 9,000+ patients finds digitalis glycosides significantly reduce worsening heart failure events, reigniting interest in a centuries-old drug.
A comprehensive review reveals how inflammaging—the fusion of aging and inflammation—fuels cardiovascular disease through senescence, mitochondrial dysfunction, and gut dysbiosis.
New JAMA research links syphilis infection to a meaningfully higher risk of certain cardiovascular outcomes, raising screening urgency.
